Literature DB >> 3574690

3-O-methyldopa and motor fluctuations in Parkinson's disease.

G Fabbrini, J L Juncos, M M Mouradian, C Serrati, T N Chase.   

Abstract

High plasma levels of 3-O-methyldopa (OMD) were found in parkinsonian patients chronically treated with levodopa, particularly in those with on-off phenomenon. However, no relation could be established between circulating levels of the levodopa metabolite and the presence of motor response fluctuations at any stage of disease. It appears unlikely that plasma OMD accumulation contributes to the pathogenesis of wearing-off or on-off responses.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3574690     DOI： 10.1212/wnl.37.5.856

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  6 in total

1.  Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.

Authors:  M Yamamoto; M Yokochi; S Kuno; Y Hattori; Y Tsukamoto; H Narabayashi; H Tohgi; Y Mizuno; H Kowa; N Yanagisawa; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  The role of 3-O-methyldopa in the side effects of L-dopa.

Authors:  Eun-Sook Y Lee; Hongtao Chen; Jennifer King; Clivel Charlton
Journal:  Neurochem Res       Date:  2007-08-24       Impact factor: 3.996

3.  Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.

Authors:  M Merello; A J Lees; R Webster; M Bovingdon; A Gordin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

4.  Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.

Authors:  T Müller; L Ander; K Kolf; D Woitalla; S Muhlack
Journal:  J Neural Transm (Vienna)       Date:  2007-06-14       Impact factor: 3.575

5.  Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.

Authors:  F Boomsma; J D Meerwaldt; A J Man in't Veld; A Hovestadt; M A Schalekamp
Journal:  J Neurol       Date:  1989-05       Impact factor: 4.849

6.  Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference.

Authors:  Thomas Müller
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.